News Room
TechnoPhage Announces First Clinical Safety Results with Innovative Biological Product TP-102
TechnoPhage is proud to announce that the first part of the Phase I/IIa Clinical Trial with TP-102 (REVERSE study) has been completed. The study...
Technophage Annual Meeting 2021
Last week TechnoPhage held its Annual Meeting where the CEO, Miguel Garcia, took the opportunity to speak to the collaborators about recent...
TechnoPhage Announces Identification of a New Antibody with Therapeutic Potential for COVID-19
We are proud to announce that a potential new therapeutic antibody for the treatment of COVID-19 has been identified. The candidate antibody was...
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology